These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16177277)

  • 41. Cognitive deficits in patients with schizophrenia: effects and treatment.
    Keefe RS
    J Clin Psychiatry; 2007; 68 Suppl 14():8-13. PubMed ID: 18284272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
    Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
    Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cognitive deficits in bipolar disorder].
    Sachs G; Schaffer M; Winklbaur B
    Neuropsychiatr; 2007; 21(2):93-101. PubMed ID: 17640495
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pretreatment predictors of cognitive deficits in early psychosis.
    González-Blanch C; Crespo-Facorro B; Alvarez-Jiménez M; Rodríguez-Sánchez JM; Pelayo-Terán JM; Pérez-Iglesias R; Vázquez-Barquero JL
    Psychol Med; 2008 May; 38(5):737-46. PubMed ID: 17922942
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can genetics inform the management of cognitive deficits in schizophrenia?
    Vyas NS; Shamsi SA; Malhotra AK; Aitchison KJ; Kumari V
    J Psychopharmacol; 2012 Mar; 26(3):334-48. PubMed ID: 22328662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence.
    Marx CE; Bradford DW; Hamer RM; Naylor JC; Allen TB; Lieberman JA; Strauss JL; Kilts JD
    Neuroscience; 2011 Sep; 191():78-90. PubMed ID: 21756978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Lack of insight in schizophrenia: a review].
    Raffard S; Bayard S; Capdevielle D; Garcia F; Boulenger JP; Gely-Nargeot MC
    Encephale; 2008 Oct; 34(5):511-6. PubMed ID: 19068341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
    Meltzer HY; Sumiyoshi T
    Behav Brain Res; 2008 Dec; 195(1):98-102. PubMed ID: 18707769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurologic comorbidities in schizophrenia.
    Nasrallah HA
    J Clin Psychiatry; 2005; 66 Suppl 6():34-46. PubMed ID: 16107182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical behavioral models for predicting antipsychotic activity.
    Castagné V; Moser PC; Porsolt RD
    Adv Pharmacol; 2009; 57():381-418. PubMed ID: 20230767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cognitive dysfunction and electroencephalogram in schizophrenia].
    Matsuoka H; Nakamura M
    Seishin Shinkeigaku Zasshi; 2005; 107(4):307-22. PubMed ID: 15920943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesizing schizophrenia: a bottom-up, symptomatic approach.
    Robbins TW
    Schizophr Bull; 2005 Oct; 31(4):854-64. PubMed ID: 16107585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project.
    Bromley E
    Schizophr Bull; 2005 Oct; 31(4):954-61. PubMed ID: 16166607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationships among cognition, motivation, and emotion in schizophrenia: how much and how little we know.
    Barch DM
    Schizophr Bull; 2005 Oct; 31(4):875-81. PubMed ID: 16079388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia.
    Lubow RE
    Schizophr Bull; 2005 Jan; 31(1):139-53. PubMed ID: 15888432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What predicts a good response to cognitive remediation interventions?
    Medalia A; Richardson R
    Schizophr Bull; 2005 Oct; 31(4):942-53. PubMed ID: 16120830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preattentional and attentional cognitive deficits as targets for treating schizophrenia.
    Braff DL; Light GA
    Psychopharmacology (Berl); 2004 Jun; 174(1):75-85. PubMed ID: 15118804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.